Objective: To evaluate efficacy of predischarge transcutaneous bilirubin (TcB) measurement and clinical risk assessment in predicting hyperbilirubinemia needing treatment.
Introduction A significant proportion of neonates develop hyperbilirubinemia needing treatment ('significant' hyperbilirubinemia) during first week of life.
1 Early discharge after birth may increase the risk of developing undetected significant hyperbilirubinemia and bilirubin-induced neurological damage. 2 Post-discharge home visits by health worker or hospital visits by family may detect significant hyperbilirubinemia, but are not universally feasible or cost-effective. Therefore, before neonates are discharged from birth, hospitals those at risk of developing high bilirubin levels need to be identified. 3 Predischarge objective assessment for risk of developing significant hyperbilirubinemia is also important because of limited accuracy of visual assessment of extent of jaundice. 4 Risk stratification for significant hyperbilirubinemia has been done by measuring bilirubin load (absolute levels or rate of rise of serum total bilirubin or transcutaneous bilirubin (TcB)), bilirubin production (exhaled carbon monoxide) and identifying underlying clinical risk factors. [5] [6] [7] The concentration of bilirubin in peripheral blood is a function of age-specific rates of bilirubin production, metabolism, excretion and reabsorption. Therefore, interpretation of bilirubin level in a neonate is based on postnatal age. The percentile location of total serum bilirubin (TSB) on an hour-specific nomogram of bilirubin levels, first described by Bhutani et al. 8 , is believed to accurately predict the risk of significant hyperbilirubinemia in North American neonates. Among various risk prediction methods, predischarge measurement of TSB has shown best discriminating ability. 9, 10 TcB has been observed to correlate well with concomitantly measured TSB. 9 TcB measurement has also been observed to minimize blood sampling for jaundice assessment.
Therefore, predischarge TcB measurement has been recommended as an accurate, non-invasive and cost-effective test for a risk-based universal bilirubin-screening program and follow-up to prevent the unexpected occurrence of severe hyperbilirubinemia. 3 Simultaneous measurement of clinical risk factors that modify the risk of significant hyperbilirubinemia can further improve the predictive ability of predischarge bilirubin measurement. However, owing to genetically determined differences in bilirubin metabolism and dissimilarities in neonatal care, especially feeding practices, clinical course of hyperbilirubinemia in Indian and Western neonates is likely to differ. In addition, accuracy of multiwavelength TcB meters that claim to neutralize the effect of darker skin color has not been proven in Indian neonates. 4 Therefore, efficacy of this non-invasive risk assessment strategy in prediction of subsequent development of significant hyperbilirubinemia needs to be investigated in Indian neonates.
We planned this prospective cohort study to construct a noninvasive predischarge risk assessment instrument in Indian neonates, and to evaluate its efficacy in predicting hyperbilirubinemia needing treatment among term and late-preterm neonates.
Methods
This study was conducted from February to June 2010 at a teaching hospital in north India. The study protocol was approved by Ethics Committee of the hospital, and written informed consent was obtained from parents.
Study design
Prospective cohort with evaluation of diagnostic test performance Subjects Inclusion criteria. Healthy neonates with gestation X35 weeks or birth weight X2000 g were eligible for enrollment in the study. Owing to logistic reasons, neonates completing 24 h of life on sunday were not eligible for enrollment in the study.
Exclusion criteria. Neonates with major congenital malformation, admission in neonatal intensive care unit or positive direct Coombs' test (was done if mother blood group was Rhesus negative), phototherapy before first bilirubin measurement or inability to come for follow-up were excluded.
Study measurements and follow-up
Clinical and epidemiological risk factors, which may influence risk of developing significant hyperbilirubinemia were recorded. Following data were recorded: birth weight, gestation, gender, maternal education and religion, parity, antenatal complications, maternal ABO and Rhesus blood group, mode of delivery, type of anesthesia used during delivery and use of oxytocin infusion during labor. In addition, age at initiation of feeding, supplemental feeding (other than breast feeding or expressed breast milk) during and subsequent to first 24 h after birth and age at passage of first stool were also noted. Clinical assessment of degree of jaundice was accompanied by TcB measurement with a multiwavelength transcutaneous bilimeter (BiliChek (Respironics, Marietta, GA, USA), coefficient of variation <5%). TcB was measured in all enrolled neonates at 24 ± 6, 72 to 96 and 96 to 144 h of postnatal age and when indicated clinically.
Blood sample for first measurement of TSB was withdrawn at the time of metabolic screening at 24 ± 6 h of postnatal age. Capillary or peripheral venous blood was collected in preheparinized microcapillaries. Blood was centrifuged immediately at 12 000 rpm for 5 min and total bilirubin was measured in separated plasma with a spectrophotometer (NEO-BIL plus, das srl (Palombara Sabina, Rome, Italy), coefficient of variation <5%). This spectrophotometer measures bilirubin using silicon photodiode detector with optical filters at 455 and 575 nm.
Neonates were followed up during hospital stay and after discharge till completion of 7th postnatal day. The timing of follow-up visit was decided based on the age at discharge. Babies discharged before 48 h of age were called back between 72 and 96 h of age and babies discharged after 48 h of age at 96 to 120 h of age. In addition to first measurement of TSB at the time of metabolic screening, two more TSB measurements were performed in each neonate. Second and third TSB measurements were done at 72 to 96 h and 96 to 144 h of postnatal age, respectively, or earlier if indicated clinically (palms/soles stained with icterus or TcB >12 mg dl À1 or >80% of age-specific phototherapy threshold).
Outcome
Key outcome was significant hyperbilirubinemia, which was defined as need of phototherapy or exchange transfusion for treatment of hyperbilirubinemia. The decision to start phototherapy was made on the basis of the age of the baby in hours and TSB levels, as per modified American Academy of Pediatrics guidelines. 3 In neonates born at X38 weeks of gestation and in neonates born at p37 completed weeks of gestation middle line and lower line of phototherapy thresholds were used to initiate phototherapy, respectively. Age-specific bilirubin on middle line is almost identical to 95th percentile values of Bhutani nomogram.
3,8
Sample size estimation In a prospective study, significant hyperbilirubinemia was observed in 10% of neonates born at X35 weeks of gestation. 5 For investigating a diagnostic test with sensitivity of at least 95% (confidence interval 5%) and a value of 0.05, we needed to enroll 1000 subjects. 12 Statistical analysis Data was analyzed using Stata 9 (StataCorp, College Station, TX, USA). Continuous data with normal distribution was analyzed by student's t-test and non-normally distributed data by Mann-Whitney U test. Categorical data was analyzed by w 2 or
Fischer's exact test. A P value of <0.05 was considered significant. Multivariate analysis was conducted using forward stepwise logistic regression analysis. The model was checked for co-linearity by calculating variance inflation factor and for extent of fitness by Hosmer-Lemeshow goodness-of-fit test. Variables observed to be significantly associated with significant hyperbilirubinemia were used for the construction of a risk assessment tool. Predictive ability was assessed by calculating sensitivity, specificity, positive predictive value and negative predictive value, by plotting receiver-operating characteristics curve and calculating c-statistic.
Results
Baseline characteristics and study flow During the study period, a total of 1255 neonates were born of which 1090 were eligible for enrollment. Among these, 93 were excluded for different reasons (Figure 1 ). A total of 997 neonates were enrolled in the study. Mean ± s.d. value for birth weight was 2627±536 g and for gestation age was 37.8±1.5 weeks (median and interquartile range (IQR): 38 and 37 to 39). Most of the study infants were born after uncomplicated antenatal course and had uneventful transition to extrauterine life. More than 80% of neonates were breastfed exclusively during the hospital stay. First measurement of bilirubin was performed at 23.3 ± 6.3 h of age. Mean TcB was 7.1±2.1 mg dl À1 and corresponding TSB was 7.0 ± 2.0 mg dl
À1
, and 29 (2.9%) neonates needed phototherapy on the basis of the first measurement of bilirubin. In these neonates, phototherapy was started at 27±5.6 h of age, with TSB levels of 12.3 ± 2.0 mg dl À1 . Remaining neonates were followed as predefined protocol. Periodic assessment of jaundice was done with measurement of both TcB and TSB. Corresponding TSB and TcB values showed good correlation and agreement (2688 paired values, correlation coefficient: 0.92; median difference: 0.2 mg dl À1 95% confidence interval: À0.7 to 1.0). Overall, a total of 199 (20%) neonates developed significant hyperbilirubinemia at a median age of 74 h (IQR: 54 to 94 h). Sixty-six (6.6%) neonates were lost to follow-up after discharge from study hospital. First TSB value in these neonates was comparable to neonates who never developed significant hyperbilirubinemia (mg dl À1 ; 6.5±1.9 versus 6.7±1.7, P ¼ 0.54), and was significantly lower than those who developed significant hyperbilirubinemia (mg dl À1 ; 6.5±1.9 versus 8.5±2.2, P ¼ 0.00).
Clinical risk factors
On univariate analysis, risk factors associated with significant hyperbilirubinemia included primiparous mother (63.3 versus 55.5%; P ¼ 0.048), previous sibling needing treatment for jaundice (15.1 versus 6.8%; P ¼ 0.02), lower gestation (in completed weeks; 38 (IQR: 36 to 39) versus 38 (IQR: 37 to 39); P ¼ 0.00), low birth weight (<2500 g: 44.2 versus 32.1%, P ¼ 0.00), supplemental feeding during first 24 h after birth (20.6 versus 14.8%; P ¼ 0.05), and presence of bruises (1 versus 0%, P ¼ 0.046) or cephalhematoma (1 versus 0%, P ¼ 0.046).
Predischarge TcB
First value of TcB obtained at 23.2±6 3 h of age was assigned to be the predischarge TcB. The 40th, 75th and 95th percentile values of predischarge TcB were 6.6, 8.6 and 11.7 mg dl À1 , respectively. In 45 (4.8%) neonates, predischarge TcB was >95th percentile (Table 1) . Of these, 28 neonates subsequently needed phototherapy (positive predictive value: 62.2%, sensitivity: 14.1%). In 379 (36.8%) neonates, predischarge TcB was <40th percentile. Of these, 349 neonates did not need subsequent treatment for hyperbilirubinemia (negative predictive value: 92.1% and specificity: 84.9%). Positive predictive value of 75th percentile cutoff was 42.2% and negative predictive value was 85.7%. Area under curve (c-statistic) for predischarge TcB percentiles was 0.72.
Construction of risk assessment tool
Forward stepwise logistic regression analysis was conducted to predict the risk of developing significant hyperbilirubinemia. Clinical risk factors with P value <0.05 on univariate analysis and predischarge TcB were entered in the regression model. On logistic regression analysis, predischarge TcB and gestation (entered as ordinal variables in three categories: 35 to 36 weeks, 37 to 38 weeks and X39 weeks) were significantly associated with significant hyperbilirubinemia (Table 2) . Hosmer-Lemeshow goodness-of-fit test indicated that the model fitted the data well (P ¼ 0.24). 
Non-invasive risk assessment for jaundice prediction S Kaur et al
A risk prediction graphical tool was constructed using TcB and gestation for prediction of subsequent significant hyperbilirubinemia (Figure 2 ). Probability of significant hyperbilirubinemia adjusted for other clinical variables can be derived by plotting TcB on the gestation-specific curves in the graph. Area under curve (c-statistic) for the graphical risk assessment tool was 0.75 (versus 0.58 for clinical risk factors alone and 0.72 for predischarge TcB alone).
Discussion
Predischarge risk assessment for subsequent development of significant hyperbilirubinemia is recommended as a potential strategy to reduce the incidence of bilirubin-induced neurological damage or kernicterus. In this prospective cohort study, we have constructed a non-invasive risk assessment graphical tool incorporating gestation at birth and TcB at 24 ± 6 h of age, and have evaluated the efficacy of this tool in predicting subsequent need of phototherapy (significant hyperbilirubinemia). TcB was measured by a multiwavelength transcutaneous bilirubinometer, which takes into account the confounding effects of the skin thickness, blood content and flow, and maturity and pigmentation (melanin and other skin chromophores). Accuracy of TcB was demonstrated by good correlation and agreement with corresponding TSB value. By itself, location of predischarge TcB in different percentile categories was able to accurately predict the subsequent risk of significant hyperbilirubinemia. Inclusion of gestation at birth observed to be significant risk factor in logistic regression analysis further improved the discriminating ability of predischarge TcB (c ¼ 0.75). Probability of significant hyperbilirubinemia can be easily derived by plotting TcB on the gestation-specific curves in the graphical tool.
Predictive ability of early transcutaneous measurement was first reported by Bhutani et al. 7 in a prospective cohort study. TcB correlated well with TSB, and 75th percentile cutoff of TcB was able to accurately identify all neonates deemed to be at risk of significant hyperbilirubinemia on simultaneous TSB measurement. Varvarigou et al. 13 constructed age-specific TcB nomogram and risk demarcation zones in Greek white neonates. At 24 h of life, the high-risk zone of the nomogram had 73.9% sensitivity in predicting significant hyperbilirubinemia, whereas the low-risk zone had 97.7% sensitivity. However, selective measurement of TSB depending on severity of TcB could have introduced verification Figure 2 Graph depicts the use of transcutaneous bilirubin measured at 18 to 30 h of postnatal age to find probability of subsequent development of significant hyperbilirubinemia in three different gestational groups.
Non-invasive risk assessment for jaundice prediction S Kaur et al bias in the study. Maisels et al. 14 presented a nomogram, based on TcB measurements obtained with the multiwavelength bilirubinometer. However, this percentile-based nomogram only represented the natural history of TcB measurements in their study population and not the predictive ability. From India, Bhat et al. 15 reported that TcB index of 7 at 24 h and 10 at 48 h can accurately predict risk of subsequent hyperbilirubinemia (TSB>17 mg dl À1 ). However, this study also suffered from verification bias as TSB measurement was performed only on 'clinical indication'. In present study, TSB was measured irrespective of TcB level and therefore verification bias was eliminated.
Discriminating ability of clinical risk factor-based approach has been reported to be lower than predischarge bilirubin measurement (TSB or TcB). Keren et al. 16 in a retrospective cohort study developed a clinical risk score and compared its performance with risk zone on bilirubin nomogram. The predischarge bilirubin risk zone had better discrimination (c ¼ 0.83) than the clinical risk factor score (c ¼ 0.71), and predicted risk of significant hyperbilirubinemia as high as 59% compared with a maximum of 44% for the clinical risk factor score. Chou et al.
17 identified maternal race, breast feeding and gestation<38 weeks as consistent predictors of TSB >20 mg dl À1 (c ¼ 0.79), and TSB> age-specific American Academy of Pediatrics criteria for considering phototherapy (c ¼ 0.69). Risk index developed by Newman et al.
18
, which includes exclusive breast feeding, family history of jaundice in a newborn, neonatal bruising, cephalohematoma, gender, gestational age, and maternal race and age>25 had better discrimination (c ¼ 0.83), but was developed using a different study design (nested case-control) to predict a different outcome (absolute TSB >25 mg dl À1 ). Comparison of the predischarge TSB risk zone to a slightly modified version of Newman's risk index (developed to predict a post-discharge TSB >20 mg dl À1 ) found that the discrimination of the TSB risk zone (c ¼ 0.79) was superior to the clinical risk factor score (c ¼ 0.69), and that neonates who subsequently develop hyperbilirubinemia have predischarge TSB values that are in higher percentiles. 19 In our study, discriminating abilities of TcB alone (c ¼ 0.72) and combined tool based on TcB and gestation at birth (c ¼ 0.75) were better than that of clinical risk factors alone (c ¼ 0.58). However, these values of c-statistics are lower than those reported by most of previous studies. Higher proportion of preterm or low birth weight neonates and higher rate of exclusive breastfeeding in our study may be the factors contributing to an increased incidence (20%) of significant hyperbilirubinemia in our study. High baseline incidence of significant hyperbilirubinemia in our study may explain the inability of lower TcB values to rule out the development of subsequent significant hyperbilirubinemia, thereby shifting the receiver-operating characteristics curve toward diagonal line and limiting the utility of predischarge TcB measurement.
Another alternative approach of risk assessment is based on predischarge TSB measurement. Risk demarcation zones developed by Bhutani et al. 8 have been reported to accurately predict subsequent hyperbilirubinemia. However, measurement of TSB needs blood sampling. In addition, laboratory measurement of TSB needs repeated standardization, and is prone to error because of difficulties with bilirubin standards, calibrators made in bovine serum and a variety of different methods for measurement. 7, 20 High inter-laboratory and intra-laboratory variability in measurement of TSB has been reported at non-research settings. 21 On the other hand, contemporary multiwavelength TcB devices have consistently demonstrated high degree of accuracy. TcB measurement are even more accurate at lower levels of bilirubin (<14 mg dl À1 ) observed during the first 48 h after birth. 4, 22 Accuracy of TcB at these levels of bilirubin, its efficacy in decreasing need of blood sampling and its cost-effectiveness have been proven in Indian neonates. 11 TcB measurement can be used as a screening tool to determine the need of TSB measurement and as a substitute to TSB measurement for risk assessment with a hour-specific TSB nomogram. 23 However, because of propensity to underestimate high bilirubin levels, TcB values >13 to 14 mg dl À1 or near phototherapy threshold need confirmation by TSB measurement.
Strengths of our study include prospective study design, large sample size, >90% follow-up rate and absence of verification bias. We could not ascertain occurrence of outcome in about 7% of enrolled neonates. However, as early TSB and demographic characteristics in these lost-to-follow-up neonates were similar to those who never developed significant hyperbilirubinemia, risk assessment instrument is unlikely to be affected. We did not use high performance liquid chromatography, which is the 'goldstandard' method for measurement of bilirubin. We measured bilirubin by a more commonly used bedside method of spectrophotometry. The bilimeter used in our study had low coefficient of variation and it was calibrated before each use.
Generalizability of observations made in the study may be influenced by relatively high incidence of hyperbilirubinemia in the study cohort because of use of lower bilirubin thresholds for starting phototherapy. Owing to lack of any population-or hospital-based data or registry, incidence of severe hyperbilirubinemia (>20 mg dl À1 ) or kernicterus cannot be estimated in India. However, in contrast to developed countries, kernicterus has been reported at lower levels of peak bilirubin in India. In a study at a tertiary care center in northern India, about one-fifth neonates with non-hemolytic jaundice and serum total bilirubin X18 mg% had kernicterus when brought to the hospital. 24 In another study on term infants with hyperbilirubinemia of mixed etiology, 10 out of 15 neonates with serum bilirubin of 21 to 25 mg dl À1 developed transient abnormalities in brainstem auditory-evoked response and 11% had developmental delay at 1 year of age. 25 These studies indicate that Indian neonates may develop bilirubin-induced neurological damage at lower peak serum bilirubin levels. In addition, about one-third neonates born in India are of low birth weight. Owing to these reasons, the National Neonatology Forum of India in its guidelines suggests use of lower thresholds for starting phototherapy, especially in areas with higher incidence of glucose-6-phosphate dehydrogenase deficiency. 26 Being non-invasive and easy-to-read, the graphical tool can potentially be used even by non-physician health workers. Using this simple strategy, community health workers can perform risk assessment and screen neonates for need of TSB measurement during the postnatal home visits. However, high initial and recurring cost of TcB devices can limit the wide uptake of this risk assessment strategy in resource-limited settings. Development of a low cost easy-to-use instrument to measure bilirubin noninvasively can benefit a vast number of neonates born in middleand low-income countries.
To conclude, each neonate should have predischarge risk assessment to predict subsequent development of significant hyperbilirubinemia. Our study demonstrates that a risk assessment tool comprising gestation at birth and early measurement of TcB can be used for this risk assessment. Baseline risk of significant hyperbilirubinemia may differ in different population groups. Therefore, further studies are needed to validate performance of this tool.
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